中國白銀(00815.HK)料去年製造業務對外銷售額跌至18.5億至19.5億人幣
中國白銀集團(00815.HK)公布,集團製造業務分部於2021年度的對外銷售金額預期介乎18.5億元至19.5億元人民幣(下同),低於截至2020年的約43.26億元,主要由於江西龍天勇的多金屬銷售在數量及種類方面均自2021年5月起減少,對外交易主要局限於銀錠訂單貿易。
製造業務分部於2020財政年度為集團貢獻約91%的總收入,對外銷售的顯著下降,連同已於2021年中期業績公告披露的江西龍天勇撇銷存貨約24.09億元,預期對2021財政年度的盈利能力產生直接且重大的負面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.